The Swedish Medicines Regulatory Authority has decided not to cover the drug semaglutide (Wegovy), which is a glucagon-like peptide-1 receptor agonist. The decision is based on concerns that the drug will be administered to patients outside the established limited criteria. Manufacturer Novo Nordisk requested a limited subsidy for adult patients with a body mass index (BMI) of at least 35 and at least three symptoms associated with being overweight, or a BMI of at least 40 with comorbidities. The application also included young people aged 12 to 18 with a BMI of 35 or higher. The Dental and Pharmaceutical Benefits Agency (TLV) rejected the application. The rationale is the high risk that more patients will take the medicine than planned, which is called "subsidy slippage". This could have major economic consequences in Sweden.